To determine the effectiveness and safety of eribulin in heavily pre-treated patients with breast cancer liver metastases (BCLM).
Key Findings:
Median progression-free survival was 3.7 months (95% CI: 2.8–4.6), with a systemic objective response rate of 15.1% (95% CI: 7.8%–25.4%; partial responses only).
The highest objective response rate (21.2%) was observed in the HR+/HER2− subtype.
Interpretation:
Eribulin-based therapy shows preliminary activity in heavily pre-treated breast cancer patients with liver metastases, suggesting potential for further investigation and emphasizing the need for larger studies.
Limitations:
Single-center study limits generalizability; findings may not apply to broader populations.
Retrospective design may introduce selection bias, affecting the reliability of results.
Small sample size may affect the robustness of findings, limiting statistical power.
Conclusion:
These findings warrant further prospective validation to confirm the efficacy and safety of eribulin in patients with BCLM, highlighting its potential role in treatment strategies.
